In this review,
we first give a brief introduction of the molecular mechanisms behind resistance, and then discuss new
strategies in small-molecule drug development to overcome influenza A virus resistance targeting mutant
M2 proteins and neuraminidases, and other viral proteins not associated with current drugs.